Full-Time
Director of Student Academic Affairs and Associate Dean
College of Arts & Sciences
Updated on 8/9/2026
Wash U
Academic research and entrepreneurial institution
Compensation Overview
$84.2k - $148.5k/yr
St. Louis, MO, USA
In Person
Bachelor's, Master's, PhD
 Education |
|---|
- Bachelor's degree and ten years of experience in an educational or academic setting, or a Master's degree and seven years of experience, or a PhD and four years of experience.
- Experience in an educational or academic setting.
- Doctoral degree is preferred.
- Leadership experience in school- and university-wide initiatives is preferred.
- Experience in a university liberal arts and sciences setting is preferred.
- Knowledge of business management, communication, confidentiality, data analysis, deadline management, decision making, diversity and inclusion, interpersonal relationships, leadership, organizing, outcomes-based education, project administration, relationship building, self-motivation, skill assessment, solution implementation, sound judgment, strategic thinking, stress management, time management, collaboration, independent work, and writing.
- Direct the development, planning, execution, and oversight of programs and events across all five Student Academic Affairs functional areas.
- Lead, mentor, and coach the senior assistant deans and develop their supervisory, management, and leadership skills.
- Facilitate collaboration among the senior assistant deans on cross-functional projects and programs.
- Align Student Academic Affairs programs and initiatives with strategic priorities of Arts & Sciences and the university.
- Lead program assessment and recommend improvements based on implementation and evaluation results.
- Recruit, hire, supervise, develop, and manage Student Academic Affairs personnel.
- Develop and implement an undergraduate recruitment strategy in partnership with the Vice Dean, Undergraduate Admissions, and the Dean's office.
- Develop and participate in recruitment and presentation sessions and oversee training for staff presenting to prospective students.
- Manage relationships with designated faculty members participating in recruitment efforts.
- Work with the Arts & Sciences Communications team on marketing and communications.
- Liaise with Arts & Sciences departments and programs to support a holistic student academic experience and integrate four-year advising with major advising.
- Serve as a primary point of contact for families of prospective and currently enrolled students.
- Participate in university committees and task forces.
- Collaborate with the Vice Dean and senior leadership on strategic growth initiatives.
- Support the development and implementation of an alumni engagement strategy for Student Academic Affairs programs and events.
- Work with the Director of Finance and Operations to set financial goals for Student Academic Affairs programs.
- Advise approximately 15 undergraduate students in each class.
- Support the College Office with additional programming and mission-critical priorities.
Wash U translates academic research into practical technologies and programs that address global challenges. The institution supports scholars through grants and partnerships to move discoveries from the lab into the public sector via entrepreneurship and technology transfer. Unlike many traditional research institutions, Wash U emphasizes a high level of financial transparency and leverages a historical connection to Nobel Laureates to foster a collaborative environment. Its goal is to use these shared visions and research initiatives to create a more equitable future and provide tangible benefits to society.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
1853
Simplify's Take
What believers are saying
- WashU projects FY27 surplus after FY26 cost cuts and spending discipline.
- The Wentzville pediatric specialty center opens in 2027, expanding patient volume and training.
- WashU's Abridge rollout cut physician pajama time 20%, strengthening clinician retention.
What critics are saying
- WashU laid off 316 staff in 2025, proving structural budget stress remains acute.
- Federal grant cuts and endowment tax pressure forced no FY26 merit raise.
- A 2026 federal civil-rights complaint targets WashU's DEI programs and could trigger funding scrutiny.
What makes Wash U unique
- WashU Medicine ranks second nationally in NIH funding, powering elite translational research.
- WashU and BJC HealthCare run Siteman Cancer Center and St. Louis Children's Hospital.
- WashU launched a Bristol Myers Squibb neuroscience collaboration on July 21, 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Company Match
Wellness Program
Mental Health Support
Parental Leave
Family Planning Benefits
Company News
WashU announces new academic-industry collaboration with Bristol Myers Squibb. Multiyear program will provide hands-on training at the pharmaceutical company, fund translational neuroscience research at WashU Washington University in St. Louis and Bristol Myers Squibb have formed a multiyear collaboration to foster scientific exchange between academia and industry in the field of neuroscience. Through this agreement, WashU medical and research trainees will have opportunities to work alongside Bristol Myers Squibb teams on select drug development projects. The collaboration builds on a long-standing research relationship aimed at combining WashU's expertise in fundamental and clinical research in neurodegenerative diseases with Bristol Myers Squibb's extensive experience in drug discovery and development. It also will provide unique opportunities for WashU Medicine trainees to gain embedded industry experience. "This partnership represents a powerful model for how academia and industry can work together to advance neuroscience," said Doug E. Frantz, WashU's vice chancellor for innovation and commercialization. "By pairing our strengths in fundamental and clinical neuroscience with Bristol Myers Squibb's deep expertise in drug development, we have an opportunity to accelerate breakthrough discoveries toward meaningful therapies for patients. At the same time, integrating our residents and fellows within Bristol Myers Squibb ensures we are training the next generation of physician-scientists in the full continuum of translational science." Each year, the program will provide funding to support up to three visiting fellows at Bristol Myers Squibb and three translational research programs at WashU in the neurosciences, with the goal of developing potential new therapeutics for neurological, neuromuscular, neuroinflammatory and psychiatric conditions. "This collaboration reinforces our commitment to working together with the goal to advance innovation that can help address significant unmet needs in neurodegenerative and neuropsychiatric diseases," said Peter Paine, head of strategic partnerships for Bristol Myers Squibb. "These conditions represent some of the greatest health challenges of our time, and we look forward to working with WashU to pursue transformational treatments for patients." WashU faculty have long collaborated with Bristol Myers Squibb on specific studies or within larger academia-industry initiatives such as the Neurofilament Light Consortium, a collaboration among WashU Medicine, University College London and several pharmaceutical companies, including Bristol Myers Squibb, to investigate neurodegenerative diseases. The new collaboration creates a formal structure to form and fund research projects in priority areas for both WashU and Bristol Myers Squibb. The goal of the agreement is ultimately to advance the field of neuroscience in ways that lead to improved treatments and patient outcomes. Private-sector partnerships with universities are usually narrow in scope, funding a pre-defined set of projects. In contrast, the high-level joint commitment of this new collaboration focuses on training the next generation of leaders in neuroscience to be proficient in both academic and industry settings. Melanie Roewe, associate vice chancellor of research administration at WashU, said that the mutual enthusiasm was reflected in the speed and ease with which the agreement came together. "This is an elevated relationship, different from most collaborations," said Roewe. "Both sides are invested in finding new and productive ways to work together and continually furthering what this collaboration can achieve." Program participation. Individuals interested in participating in the visiting fellows program or the translational neuroscience research program are encouraged to submit an expression of interest by Sept. 1. For additional information regarding eligibility, participation and the expression-of-interest process, reach out to Mark Van Horn, senior director of business development, Strategic External Projects and Outreach, at [email protected]. About WashU Medicine WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with more than 3,000 faculty. Its National Institutes of Health (NIH) research funding portfolio is the second largest among U.S. medical schools and has grown 83% since 2016. Together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently among the top five in the country, with more than 2,000 faculty physicians practicing at 130 locations. WashU Medicine physicians exclusively staff Barnes-Jewish and St. Louis Children's hospitals - the academic hospitals of BJC HealthCare - and Siteman Cancer Center, a partnership between BJC HealthCare and WashU Medicine and the only National Cancer Institute-designated comprehensive cancer center in Missouri. WashU Medicine physicians also treat patients at BJC's community hospitals in its region. With a storied history in MD/PhD training, WashU Medicine recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.
Global AI movements & new biological pathways. Focus: Aligning Glassbury AI's engineering approach with the massive global computational shift and a newly discovered cellular death mechanism. 1. "The C-BRAIN consortium: what an 'AI biomedical research scientist' means for Glassbury's tech stack" * The Hook: On July 13, 2026, a global coalition of academic centers (led by WashU Medicine) and pharma giants launched C-BRAIN. Its mission? Building open-source AI tools to attack the notorious 99% failure rate of neurodegenerative clinical trials by synthesizing "dark" (unpublished) data and clinical literature. * The Angle: Write an insider piece on how Glassbury AI views this watershed moment. Explain that the era of isolated, proprietary "black box" medical AI is ending. Detail how Glassbury's own pipelines plan to leverage and interface with C-BRAIN's open-source frameworks, establishing Glassbury as an early adopter of standardized, collaborative medical AI. * Why It Matters Now: This is the biggest medical-AI news of the summer. Aligning Glassbury with a major global consortium shows that your team is at the absolute forefront of industry standards.
Neuraptive secures exclusive licence from Washington University for nerve device. The newly licensed device will be added to Neuraptive's portfolio, which includes NTX-001, currently in Phase III clinical evaluation. Neuraptive Therapeutics has secured an exclusive licence from Washington University in St Louis for a bioresorbable wireless electronic stimulation device designed for peripheral nerve repair. The technology, which was developed at Washington University School of Medicine (WashU Medicine) in collaboration with Northwestern University, delivers targeted electrical pulses to damaged nerves to support regeneration. The device is said to be fully bioresorbable and does not require a second procedure for removal, as it naturally breaks down in the body over time. The newly licensed device will be added to Neuraptive Therapeutics' existing portfolio, which includes NTX-001, a nerve fusion system currently being studied in a Phase III trial for surgical repair of transected peripheral nerves. Washington University in St Louis office technology management assistant vice chancellor and managing director Nichole Mercier said: "WashU is excited to partner with an emerging company like Neuraptive to support the development of the bioresorbable platform originating from its research labs. "This agreement enables the platform to be further developed to advance peripheral nerve repair and have patient impact." Neuraptive Therapeutics chairman and CEO Bob Radie said: "This deal is a meaningful step in strengthening its portfolio and offering more options for patients facing nerve injuries. "The bioresorbable stimulator has real potential either on its own for repairing severed nerves or as a synergistic complement to its lead product candidate, NTX-001. "Medical Device Network also intend to build on promising early research into the device's ability to help speed recovery from crushed nerves. "Overall, this technology could add a broader set of tools for surgeons and patients, aiming for better functional recovery, fewer long-term issues, and improved quality of life after these challenging injuries." Earlier this year, Washington University School of Medicine (WashU Medicine) researchers developed an Alzheimer's blood test symptom prediction model that estimates when individuals may begin to show signs of the disease. Give your business an edge with its leading industry insights.
News & articles. At ConnectWeb Connectweb has a team of editors and researchers collating the most relevant information to you and your industry. All Directories' publications and sites provide a wealth of information for research or marketing, and are used by public and corporate libraries, educational institutions, government departments, corporations and SMEs across the country. You are here: Home News Access the latest company news and announcements distributed through Medianet. Medical, Health & Aged Care 14/07/2026 22:18 Neuraptive Therapeutics licenses innovative bioresorbable nerve stimulation technology from Washington University in St. Louis. Neuraptive Therapeutics, Inc. CHESTERBROOK, Pa.-BUSINESS WIRE- Neuraptive Therapeutics, Inc., a clinical-stage biotech company focused on peripheral nerve injuries, announced today that it has secured an exclusive license from Washington University in St. Louis for a bioresorbable wireless electronic stimulation device. Developed by researchers at WashU Medicine in collaboration with Northwestern University, the technology delivers targeted electrical pulses to damaged nerves to speed up regeneration. The device is fully bioresorbable, meaning it breaks down naturally in the body and doesn't require a follow-up surgery for removal. "WashU is excited to partner with an emerging company like Neuraptive to support the development of the bioresorbable platform originating from our research labs," said Nichole R. Mercier, PhD, Assistant Vice Chancellor and Managing Director for the Office of Technology Management at WashU. "This agreement enables the platform to be further developed to advance peripheral nerve repair and have patient impact." Bob Radie, Chairman and Chief Executive Officer of Neuraptive Therapeutics, said, "This deal is a meaningful step in strengthening our portfolio and offering more options for patients facing nerve injuries. The bioresorbable stimulator has real potential either on its own for repairing severed nerves or as a synergistic complement to our lead product candidate, NTX-001. We also intend to build on promising early research into the device's ability to help speed recovery from crushed nerves. Overall, this technology could add a broader set of tools for surgeons and patients - aiming for better functional recovery, fewer long-term issues, and improved quality of life after these challenging injuries." The new device complements Neuraptive's existing pipeline, including NTX-001, which is currently in a Phase 3 trial for the surgical repair of transected peripheral nerves. It fits squarely with the company's strategy of combining therapeutics, delivery systems, and enabling technologies to tackle unmet needs in this space. Financial terms of the licensing agreement were not disclosed. About Neuraptive Neuraptive Therapeutics is a biotechnology company developing novel therapies and medical products to improve outcomes for patients and surgeons dealing with peripheral nerve injuries. The company's lead program, NTX-001, is a nerve fusion system designed to restore electrical continuity across severed nerves. For more information, visit www.neuraptive.com. Contact details: * images - ntx_logo2022.jpg download. ConnectWeb. ConnectWeb is Australia's leading publisher of biographical data, directories and specialist newsletters. With ConnectWeb you gain access to its comprehensive database of contacts and companies in media, government and associations. Connect with Connectweb.
AI platform reduces paperwork for WashU Medicine and BJC physicians. Less time on documentation means more time to focus on patients A doctor's workday often extends beyond the time spent with patients - typing up notes after patient visits can take a few hours daily. Most physicians say they would rather devote their mental energy to patient care than to such administrative tasks. To help ease that burden, WashU Medicine and BJC Health recently made a clinical artificial intelligence (AI) platform available to physicians that captures and summarizes what is said during medical appointments, allowing doctors to focus on interacting directly with their patients and less on note-taking. The joint Center for Health AI (CHAI) vetted the technology and is leading the rollout, starting with outpatient clinics. The center, established as part of the long-term affiliation agreement between WashU Medicine and BJC Health, is focused on developing and evaluating AI technologies to make healthcare more personalized and effective for patients and more efficient for providers. Doctors who use the platform find that it can save time and effort over manually typing up notes or transcribing recorded notes. "This resource allows us to spend more time engaging directly with patients and still produces records that are very accurate. The platform captures the relevant aspects of the patient-clinician conversation and is generated within 30 seconds or a minute," said Sam Bhayani, MD, who is a member of CHAI's executive team as the chief medical officer for WashU Medicine Physicians, the clinical practice group that includes more than 2,550 primary care and specialist physicians. The AI note-taking platform, called Abridge, is simple to use with a smartphone: After obtaining patient consent, the physician opens an app on their phone and the technology "listens" to the visit and generates notes that summarize the discussion. Bhayani, who is also the the Robert Killian Royce, M.D., Distinguished Professor in the Division of Urology in the Mary Culver Department of Surgery, explained that the physician can then review the notes, refer back to the transcript if necessary, and make edits and additions before adding them to the patient's electronic medical record - a much less time-consuming process than drafting notes from scratch. A pilot study of the platform and other similar options, conducted by CHAI and involving nearly 500 WashU Medicine and BJC physicians, generated overwhelmingly positive feedback from the doctors, Bhayani added. Early studies indicated that users of the Abridge platform had a 20% reduction in "pajama time" - the after-hours work physicians often put in to draft patient notes. Philip Payne, PhD, the Janet and Bernard Becker Professor at WashU Medicine and chief health AI officer for BJC Health and WashU Medicine, said the adoption of the Abridge platform represents a long-term commitment by both institutions to push healthcare innovation forward using validated AI technologies. "CHAI has a lot of high-level expertise to evaluate the impact of AI platforms like this in all facets of healthcare, ensuring that they are effective at improving clinical outcomes, provider well-being and patient experience," said Payne, adding that the rigor WashU Medicine and BJC Health bring to assessing the utility and reliability of these platforms means that decisions made here can provide a model for other healthcare systems looking to adopt these technologies. "If the AI platform improves quality, safety, outcomes and value of care at WashU Medicine and BJC Health, then other people will look to see how we made that work, and it will have a demonstrably positive impact for patients and communities elsewhere," he said. A commitment to innovation. The time-saving potential of the platform is significant: Surveys by the American Medical Association have shown that physicians often need to spend extra time on top of their normal working hours on tasks related to electronic health records, including transcription, inputting additional notes after a visit or cleaning up notes. Jennifer Schmidt, MD, an associate professor of medicine and associate chief of clinical operations in the WashU Medicine Division of General Medicine & Geriatrics, said she was surprised to find that even better than clearing her time, using the platform cleared her mind. "I had not anticipated how much it reduces your cognitive burden so you can focus on what your patients are saying and what it means for their care, rather than trying to multitask," said Schmidt. "For patients with more complex conditions, where there are detailed descriptions of their symptoms, this platform is really helpful because you're not focusing on trying to write down everything they say." Schmidt said she has seen how adoption of the platform has allowed her and her colleagues to close out their notes more quickly. She noted that WashU Medicine's proactive commitment to the technology positions it well to attract physicians who want to use these platforms in their practice. "Ambient AI like this is going to be adopted everywhere, and investing in it is really important," Schmidt said. "Physicians looking to work here want to have these platforms. This is medicine's future." To help clinicians adopt the technology, Abridge representatives visit the WashU Medicine and BJC Health campuses on a quarterly basis. Physicians and staff who want to learn more about using the ambient AI platform, attend a demonstration, or speak with clinical leaders can receive updates on upcoming campus visits by completing an online form. About WashU Medicine WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 3,100 faculty. Its National Institutes of Health (NIH) research funding portfolio is the second largest among U.S. medical schools and has grown 78% since 2016. Together with institutional investment, WashU Medicine commits over $1.6 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently among the top five in the country, with more than 2,550 faculty physicians practicing at 200 locations. WashU Medicine physicians exclusively staff Barnes-Jewish and St. Louis Children's hospitals - the academic hospitals of BJC HealthCare - and Siteman Cancer Center, a partnership between BJC HealthCare and WashU Medicine and the only National Cancer Institute-designated comprehensive cancer center in Missouri and southern Illinois. WashU Medicine physicians also treat patients at BJC's community hospitals in its region. With a storied history in MD/PhD training, WashU Medicine recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.